Vicarious Surgical Begins Quotation on the OTCQB as Part of Strategic Path Toward Potential Nasdaq Listing
Rhea-AI Summary
Vicarious Surgical (OTCQB: RBOT) announced its Class A common stock began quotation on the OTCQB on March 24, 2026, marking a step in its capital markets strategy toward a potential Nasdaq Capital Market listing.
The company said trading on the OTCQB could improve market visibility, attract market maker participation, and support liquidity as it advances operational milestones, including a targeted design freeze by the end of 2026.
Positive
- OTCQB quotation began on March 24, 2026
- Aimed Nasdaq relisting as part of broader capital markets strategy
- Targeted design freeze by end of 2026
Negative
- Nasdaq listing remains potential and is not guaranteed
- OTCQB tier is a secondary venue compared with national exchanges
News Market Reaction – RBOT
In the Mar 26 session, RBOT declined 5.56%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 16 | Listing strategy update | Positive | +29.4% | Outlined plan to pursue Nasdaq relisting with lower 2026 cash burn. |
| Mar 09 | Earnings report | Positive | +24.3% | Reported lower operating expenses, narrower losses, and reduced 2026 cash burn outlook. |
| Mar 04 | NYSE delisting notice | Negative | -53.2% | Received NYSE delisting notice after falling below $15M market cap standard. |
| Jan 12 | Clinical progress update | Positive | +2.3% | Completed successful in‑vivo porcine lab advancing system toward 2026 design freeze. |
| Dec 29 | Operating partnership | Positive | -1.1% | Announced software execution partnership to streamline development and cut costs. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news catalysts have mostly led to price moves consistent with headline tone, with only one mild divergence on an operating partnership update.
Over the past few months, RBOT has combined operational progress with significant listing transitions. A Dec 2025 software partnership aimed to streamline development, followed by a Jan 2026 successful in‑vivo porcine lab supporting a targeted design freeze by end of 2026. In March 2026, an NYSE delisting notice was followed by a strategic plan to pursue a Nasdaq relisting and reduced cash burn. Today’s OTCQB upgrade fits into this ongoing capital markets repositioning.
Key Terms
otcqb financial
market maker financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Application to upgrade market tier approved
WALTHAM, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the “Company”), today announced that it has received approval for its Class A common stock to upgrade to the OTCQB® Venture Market by OTC Markets Group Inc. (the “OTCQB”). The Company’s Class A common stock has begun quotation on the OTCQB as of March 24, 2026, under the ticker symbol RBOT. This milestone represents a key step in the Company’s broader capital markets strategy as it advances toward a potential listing on the Nasdaq Capital Market.
The OTCQB is designed for early-stage and developing companies and supports enhanced market transparency and trading efficiency. The Company believes that trading on the OTCQB would improve market visibility and facilitate increased market maker participation, which may enhance trading liquidity and support its broader strategy to relist on a national exchange, including its previously announced efforts to pursue a Nasdaq listing.
“We are pleased to achieve this important step in our capital markets strategy as we continue to advance toward design freeze by the end of 2026,” said Stephen From, Chief Executive Officer of Vicarious Surgical. “Trading on the OTCQB enhances accessibility and liquidity for our shareholders and represents a foundational step as we execute on our previously announced plan to pursue a Nasdaq listing. We believe these actions, combined with our continued operational progress, position us to re-engage with a broader investor base over time.”
About Vicarious Surgical
Founded in 2014, Vicarious Surgical is a next-generation surgical robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and has received backing by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.
In accordance with guidance provided by the SEC regarding use by a company of its websites and social media channels as a means to disclose material information to investors and to comply with its disclosure obligations under Regulation FD, the Company hereby notifies investors, the media and other interested parties that it intends to continue to use its investor relations website (https://investor.vicarioussurgical.com/), its LinkedIn page (https://linkedin.com/company/vicarious-surgical/) and its X feed (@VicariousSurg) to publish important information about the Company, including information that may be deemed material to investors. The list of social media channels that the Company uses may be updated on its investor relations website from time to time. The Company encourages investors, the media, and other interested parties to review the information the Company posts on its website and social media channels as described above, in addition to information announced by the Company through its SEC filings, press releases and public conference calls and webcasts.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein, including without limitation, statements regarding the timeline for design freeze for the Vicarious Surgical System, the Company’s intention to list its Class A common stock on the Nasdaq Capital Market, the anticipated benefits of quotation on the OTCQB Venture Market such as market visibility, market maker participation and enhanced trading liquidity, and the potential to re-engage with a broader investor base, are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the Company’s ability to obtain and maintain listing on a national securities exchange; the impacts of the Company’s reduced cash burn; the price of the Class A common stock following any reverse stock split; the Company’s future business strategy; the approval, commercialization and adoption of the Company’s initial product candidates and the success of its single-port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and service offerings; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product and service development activities; the potential attributes and benefits of the Company’s product candidates and services; the Company’s ability to obtain and maintain regulatory approval for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical System; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing license, manufacture, supply and distribution agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; economic downturns, political and market conditions and their potential to adversely affect the Company’s business, financial condition and results of operations; the Company’s intellectual property rights and its ability to protect or enforce those rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties indicated from time to time in the Company’s filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Investor Contact
ir@vicarioussurgical.com
Media Inquiries
media@vicarioussurgical.com
Source: Vicarious Surgical Inc.
